In Vitro Comparative Study of Platelets Treated with Two Pathogen-Inactivation Methods to Extend Shelf Life to 7 Days

Background and Objectives: Since 2015, platelet products have been pathogen-inactivated (PI) at the Luxemburgish Red Cross (LRC) using Riboflavin and UV light (RF-PI). As the LRC should respond to hospital needs at any time, platelet production exceeds the demand, generating a discard rate of 18%. To reduce this, we consider the extension of storage time from 5 to 7 days. This study’s objective was to evaluate the in vitro 7-day platelet-storage quality, comparing two PI technologies, RF-PI and amotosalen/UVA light (AM-PI), for platelet pools from whole-blood donations (PPCs) and apheresis platelets collected from single apheresis donation (APCs). Materials and Methods: For each product type, 6 double-platelet concentrates were prepared and divided into 2 units; one was treated with RF-PI and the other by AM-PI. In vitro platelet-quality parameters were tested pre- and post-PI, at days 5 and 7. Results: Treatment and storage lesions were observed in PPCs and APCs with both PI methods. We found a higher rate of lactate increase and glucose depletion, suggesting a stronger stimulation of the glycolytic pathway, a higher Annexin V binding, and a loss of swirling in the RF-PI-treated units from day 5. The platelet loss was significantly higher in the AM-PI compared with the RF-PI units. Conclusions: Results suggest that RF-PI treatment has a higher deleterious impact on in vitro platelet quality compared to AM-PI, but we observed higher loss of platelets with AM-PI due to the post-illumination amotosalen adsorption step. If 7-day storage is needed, it can only be achieved with AM-PI, based on our quality criteria.

[1]  M. Díaz-Ricart,et al.  Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic , 2021, Transfusion.

[2]  C. McDonald,et al.  Assessing the inactivation capabilities of two commercially available platelet component pathogen inactivation systems: effectiveness at end of shelf life , 2021, Vox sanguinis.

[3]  W. Rabitsch,et al.  The assessment of platelet function by thromboelastometry as a point‐of‐care test to guide Intercept‐treated platelet support in hemato‐oncological patients and hematopoietic stem cell transplantation recipients , 2020, Transfusion.

[4]  C. Gorria,et al.  Impact of implementing pathogen reduction technologies for platelets on reducing outdates , 2019, Vox sanguinis.

[5]  A. Buser,et al.  Clinical impact of amotosalen‐ultraviolet A pathogen‐inactivated platelets stored for up to 7 days , 2019, Transfusion.

[6]  V. Compernolle,et al.  Biomolecular Consequences of Platelet Pathogen Inactivation Methods. , 2019, Transfusion medicine reviews.

[7]  P. Sandgren,et al.  Optimized processing for pathogen inactivation of double‐dose buffy‐coat platelet concentrates: maintained in vitro quality over 7‐day storage , 2018, Vox sanguinis.

[8]  T. Jimenez‐Marco,et al.  Our experience in riboflavin and ultraviolet light pathogen reduction technology for platelets: from platelet production to patient care , 2018, Transfusion.

[9]  T. Hervig,et al.  Hemostatic efficacy of pathogen-inactivated-versus untreated-platelets : a randomized controlled trial , 2018 .

[10]  D. Devine,et al.  Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets , 2018, Front. Med..

[11]  E. Deconinck,et al.  Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial , 2018, JAMA oncology.

[12]  Abdimajid Osman,et al.  The platelets’ perspective to pathogen reduction technologies , 2018 .

[13]  C. Gachet,et al.  Amotosalen/UVA pathogen inactivation technology reduces platelet activability, induces apoptosis and accelerates clearance , 2017, Haematologica.

[14]  J. Cid.  Prevention of transfusion‐associated graft‐versus‐host disease with pathogen‐reduced platelets with amotosalen and ultraviolet A light: a review , 2017, Vox sanguinis.

[15]  T. Lüscher,et al.  Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance , 2017, Haematologica.

[16]  M. Graf,et al.  Clinical effectiveness of platelets in additive solution treated with two commercial pathogen‐reduction technologies , 2017, Transfusion.

[17]  R. Benjamin,et al.  Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre , 2017, Vox sanguinis.

[18]  M. Villamayor,et al.  Assessment of the Clinical Performance of Platelet Concentrates Treated by Pathogen Reduction Technology in Santiago de Compostela , 2016, Transfusion Medicine and Hemotherapy.

[19]  N. Lion,et al.  In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB‐treated platelet concentrates , 2015, Transfusion.

[20]  N. Lion,et al.  In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step. , 2015, Blood transfusion = Trasfusione del sangue.

[21]  D. Devine,et al.  p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment , 2014, Transfusion.

[22]  P. Schlenke.  Pathogen Inactivation Technologies for Cellular Blood Components: an Update , 2014, Transfusion Medicine and Hemotherapy.

[23]  D. Devine,et al.  Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus. , 2014, Transfusion medicine reviews.

[24]  C. Saunders,et al.  Impact of glucose and acetate on the characteristics of the platelet storage lesion in platelets suspended in additive solutions with minimal plasma , 2013, Vox sanguinis.

[25]  J. Cazenave,et al.  Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation , 2013, Transfusion.

[26]  D. Marks,et al.  In vitro assessment of buffy‐coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system , 2013, Transfusion medicine.

[27]  A. Castrillo,et al.  Treatment of Buffy Coat Platelets in Platelet Additive Solution with the Mirasol® Pathogen Reduction Technology System , 2013, Transfusion Medicine and Hemotherapy.

[28]  G. Escolar,et al.  Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta‐analysis of randomized controlled trials , 2012, Vox sanguinis.

[29]  D. Marks,et al.  Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling , 2012, Transfusion.

[30]  S. Marschner,et al.  Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation , 2011, Transfusion.

[31]  C. Prowse,et al.  A multi‐centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion , 2011, British journal of haematology.

[32]  A. Galán,et al.  Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function , 2011, Transfusion.

[33]  P. Mintz,et al.  A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology , 2010, Transfusion.

[34]  M. Andreeff,et al.  Platelet senescence and phosphatidylserine exposure , 2010, Transfusion.

[35]  B. Gathof,et al.  Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies , 2009, Transfusion.

[36]  B. Gathof,et al.  Functional characteristics of apheresis‐derived platelets treated with ultraviolet light combined with either amotosalen‐HCl (S‐59) or riboflavin (vitamin B2) for pathogen‐reduction , 2009, Vox sanguinis.

[37]  K. R. Resmi,et al.  Suitability of measurement of swirling as a marker of platelet shape change in concentrates stored for transfusion , 2006, Platelets.

[38]  R. Cardigan,et al.  Current methods of assessing platelet function: relevance to transfusion medicine , 2005, Vox sanguinis.

[39]  J. Fridey,et al.  Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. , 2004, Blood.

[40]  B. Gathof,et al.  Functional characteristics of buffy‐coat PLTs photochemically treated with amotosalen‐HCl for pathogen inactivation , 2004, Transfusion.

[41]  H. Gulliksson.  Defining the optimal storage conditions for the long-term storage of platelets. , 2003, Transfusion medicine reviews.

[42]  J. Freedman,et al.  Platelet apoptosis in stored platelet concentrates and other models. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[43]  F. Peccatori,et al.  The absence of swirling in platelet concentrates is highly predictive of poor posttransfusion platelet count increments and increased risk of a transfusion reaction , 2000, Transfusion.

[44]  Napier.  Guide to the Preparation, Use and Quality Assurance of Blood Components. , 1998 .

[45]  S. Holme.  Storage and Quality Assessment of Platelets , 1998, Vox sanguinis.

[46]  S Murphy,et al.  A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice , 1996, Transfusion.

[47]  S. Murphy.  METABOLIC PATTERNS OF PLATELETS‐IMPACT ON STORAGE FOR TRANSFUSION , 1994, Vox sanguinis.

[48]  O. Q. Hyder.  Reaction , 1973 .

[49]  J. J. Loghem,et al.  The International Society of Blood Transfusion , 1963 .